Drug intelligence / Profile preview

Huangjin Shuangshen

Development stage: Preclinical
Lead developer: Zhejiang Chinese Medical University
Administration: Oral

Overview

Huangjin Shuangshen is a traditional Chinese medicine (TCM) formulation, specifically prepared as granules, currently under investigation for its therapeutic potential. It is being studied for the treatment of gastric cancer and for managing anxiety and depression following coronary stent implantation. The drug is administered orally.

Brand names: Huangjin Shuangshen Granules
Other names: Huangjin Shuangshen GranulesHuangjinshuangshenjiawei Granules黄金双参加味颗粒口服黄金双参加味颗粒

Targets

CCL2 (C-C motif chemokine 2)TNFA (Tumor necrosis factor alpha (soluble))ACE (Angiotensin Converting Enzyme)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IL-6 (Interleukin 6)CXCL10 (C-X-C Motif Chemokine Ligand 10)IFNG (Interferon gamma)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Huangjin Shuangshen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huangjin Shuangshen.

Explore the full profile